Suppression by γ-hydroxybutyric acid of “alcohol deprivation effect” in rats: preclinical evidence of its anti-relapse properties

Giancarlo Colombo *, Mauro A. M. Carai and Gian Luigi Gessa

Section of Cagliari, Neuroscience Institute, National Research Council of Italy, Monserrato, Italy

INTRODUCTION

The short-chain fatty acid, γ-hydroxybutyric acid (GHB; see Snead and Gibson, 2005; Agabio et al., 2010), has been used for years—in some European Countries—in the treatment of alcohol dependence. Several open and double-blind clinical surveys indicate indeed that GHB administration reduced alcohol craving and consumption, promoted abstinence, and ameliorated alcohol withdrawal syndrome in alcoholics. Specifically, a small double-blind study (Gallimberti et al., 1992) and some subsequent open studies (Addolorato et al., 1996, 1998; Moncini et al., 2000; Maremmani et al., 2001; Caputo et al., 2003, 2007, 2011) indicated that treatment with GHB was effective in reducing alcohol drinking, promoting abstinence, and controlling craving for alcohol (for review, see Agabio and Gessa, 2002; Addolorato et al., 2009). Further, three double-blind studies (Gallimberti et al., 1989; Addolorato et al., 1999a; Nimmerrichter et al., 2002) and some additional open studies (Nava et al., 2007; Elsing et al., 2009) reported that treatment with GHB was also effective in suppressing the symptomatology of alcohol withdrawal syndrome (for review, see Agabio and Gessa, 2002; Addolorato et al., 2009). In terms of mechanism of action, the similarity of the pharmacological profile of GHB and alcohol has led to hypothesize that the suppressing effects exerted by GHB on alcohol withdrawal syndrome, alcohol consumption, and craving for alcohol may be due to the “substitution” of alcohol actions, similar to methadone in heroin addiction (see Agabio and Gessa, 2002; Addolorato et al., 2009). As predictable on the basis of a number of clinical and preclinical observations (see Nicholson and Balster, 2001; Drasbek et al., 2006), the major limitation of the therapeutic use of GHB appears to be its abuse potential: a portion of patients undergoing GHB treatment voluntarily increased their daily GHB dosage (although some of these self-administered increases were made in an attempt to achieve more effective therapeutic doses) (Addolorato et al., 1996; Gallimberti et al., 2000; Glisson and Norton, 2002; Caputo et al., 2011) and some patients even developed dependence on GHB (Addolorato et al., 1999b; see also Caputo et al., 2009).

Treatment with GHB reduced several alcohol-related behaviors also in laboratory rodents. Specifically, administration of non-sedative doses of GHB markedly reduced voluntary alcohol intake in selectively bred, Indiana alcohol-preferring (June et al., 1995) and Sardinian alcohol-preferring (sP) (Agabio et al., 1998) rats exposed to the standard, homecage two-bottle “alcohol vs. water” choice regimen. Additionally, administration of non-sedative doses of GHB reduced the motivational properties of alcohol (the animal correlate of human craving for alcohol), measured in sP rats exposed to sessions of operant, oral alcohol self-administration under the progressive ratio schedule of reinforcement (Maccioni et al., 2008). Treatment with non-sedative doses of GHB also reduced alcohol-seeking behavior, measured in sP rats initially trained to lever-respond for alcohol under a standard procedure of oral alcohol self-administration and then exposed, in the test session, to extinction responding (non-reinforced lever-responding was used as index of alcohol-seeking behavior) (Maccioni et al., 2008). Finally, administration of GHB resulted in the complete suppression of the severity of alcohol withdrawal signs in rats made physically dependent on alcohol by the repeated, forced administration of intoxicating doses of alcohol (Fadda et al., 1989).

The present study was designed to extend to alcohol relapse-like drinking the investigation on the capacity of GHB to suppress different alcohol-related behaviors in rats. To this end, sP rats were exposed to the “alcohol deprivation effect” (ADE) paradigm, a...
validated animal model of relapse episodes occurring in human alcoholics. Relapse to heavy alcohol drinking, together with loss of control over alcohol, represent the core features of alcohol addiction in humans (see Morse and Flavin, 1992; Kleber et al., 2007). ADE is defined as the temporary increase in alcohol drinking occurring after a period of alcohol abstinence (see Spanagel, 2005; Martin-Fardon and Weiss, 2013). Rats of the sP line constitute a good experimental model for investigations on ADE. Indeed, sP rats display robust, although transient, increases in alcohol intake after a period of alcohol deprivation of at least 1 week: over the first hour of re-access to alcohol, alcohol intake in sP rats is usually double than that recorded in control, alcohol-non-deprived rats (e.g., Agabio et al., 2000; Serra et al., 2003).

MATERIALS AND METHODS
All experimental procedures employed in the present study were in accordance with the Italian Law on the “Protection of animals used for experimental and other scientific reasons.”

ANIMALS
Male sP rats (see Colombo et al., 2006a; Bell et al., 2012), from the 71st generation and 75-days-old at the start of the study, were used. Rats were individually housed in standard plastic cages with wood chip bedding. The animal facility was under an inverted 12:12 h light-dark cycle (lights on at 23:00), at a constant temperature of 23 ± 2°C, and relative humidity of approximately 60%. Rats were extensively habituated to handling and intraperitoneal injections. Standard rat chow (Mucedola, Settimo Milanese, Italy) was always available.

EXPERIMENTAL PROCEDURE
Rats (n = 64) were continuously offered alcohol (10% v/v, in water) and water under the standard, homecage two-bottle choice regimen, with unlimited access for 24 h/day and for four consecutive weeks. Alcohol, water, and food intake was monitored once a day by weighing the bottles and food pellets (0.1-g accuracy) immediately before the onset of the dark phase. Bottles were refilled every day with fresh solution and their left-right positions interchanged daily.

At the end of the 4-week period of access to alcohol and water, during which rats consumed daily an average of approximately 6 g/kg alcohol, rats were divided into two groups (n = 32) matched for body weight as well as alcohol and water intake over the last 7 days. One rat group was deprived of alcohol for 14 consecutive days, during which water was the sole fluid available (alcohol-deprived rats). The second rat group continued to have unlimited access to alcohol and water (alcohol-non-deprived rats), with the exception of the last 6 h before GHB injection, when the alcohol bottle was removed to ensure that blood alcohol levels were equal to zero at the time of the test.

At the end of the 14th day of the deprivation phase, rats of both groups were divided into four subgroups (n = 8), matched for body weight, and injected acutely and intraperitoneally with 0, 100, 200, and 300 mg/kg GHB. GHB (sodium salt; Laboratorio Farmaceutico CT, Sanremo, Italy) was dissolved in distilled water (3.4% w/v; this concentration (kept fixed in the three doses of GHB) was chosen to minimize tissue irritation at the injection site (e.g., Maccioni et al., 2008)) and administered 10–15 min before lights off. Control rats (0 mg/kg GHB) were treated with an equal volume of saline. Alcohol was represented at lights off. Alcohol, water, and food intake was recorded 60 min later (i.e., the time interval during which sP rats display the most pronounced ADE; e.g., Agabio et al., 2000; Serra et al., 2003).

DATA ANALYSIS
Data on the effect of treatment with GHB on alcohol, water, and food intake during the 60-min observation period were expressed in g/kg, ml/kg, and g/kg, respectively, and analyzed by separate two-way (deprivation; treatment) ANOVAs, followed by the Newman–Keuls test for post hoc comparisons.

RESULTS
ANOVA indicated significant effects of both deprivation [F(1, 56) = 31.99, P < 0.0001] and treatment with GHB [F(3, 56) = 6.44, P < 0.001], and a significant interaction [F(3, 56) = 3.48, P < 0.05], on alcohol intake during the first hour of the post-deprivation phase. Alcohol intake in vehicle-treated alcohol-deprived rats was approximately 90% higher than that recorded in vehicle-treated alcohol-non-deprived rats (Figure 1), indicative of the development of ADE. Post hoc analysis indicated that all doses of GHB suppressed ADE, as alcohol intake in all GHB-treated alcohol-deprived rat groups was significantly lower than that recorded in vehicle-treated alcohol-deprived rats (Figure 1);
The results of the present study indicate that acute treatment with GHB suppressed the extra-amount of alcohol (ADE) voluntarily consumed by alcohol-prefering sP rats after a 2-week period of forced abstinence from alcohol. As ADE has been proposed and validated as an animal model of relapse episodes occurring in human alcoholics (see Spanagel, 2005; Martin-Fardon and Weiss, 2013), these data extend to relapse-like drinking the capacity of GHB to suppress different alcohol-related behaviors, including alcohol drinking under the two-bottle choice regimen (June et al., 2005), and alcohol-seeking behavior (Maccioni et al., 2008), in alcohol-prefering rats. These data are also in close agreement with the results of a number of clinical surveys reporting the capacity of GHB to promote and maintain alcohol abstinence and to prevent alcohol relapse (Gallimberti et al., 1997; Lingenhoehl et al., 1999; for review, see Bernasconi et al., 2005). Accordingly, the results of the present study may be interpreted suggesting that GHB suppressed relapse-like drinking via activation of the GABA_B receptor. This interpretation is in line with the results of recent studies demonstrating that the GABA_B receptor agonists, baclofen and CGP 44532, dose-dependently suppressed ADE in sP rats (Colombo et al., 2003, 2006b; Carai et al., 2005).

ACKNOWLEDGMENTS

The authors are grateful to Mrs. Carla Acciaro for animal breeding and care, and Ms. Anne Farmer for language editing of the manuscript. This work has been supported by grant no. CRP-17596 from Regione Autonoma della Sardegna (L.R. 7 agosto 2007, n. 7).

REFERENCES

Addolorato, G., Balducci, G., Caprizzo, E., Attilia, M. L., Taggi, G., Gasbarrini, G., et al. (1999a). Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol. Clin. Exp. Res. 23, 1596-1604.

Addolorato, G., Caputo, F., Caprizzo, E., Bernardi, M., Stefanini, G. F., and Gasbarrini, G. (1999b). A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin. Neuropsychopharmacol. 22, 60-62.

Addolorato, G., Castelli, E., Stefanini, G. F., Casella, G., Caputo, F., Marsigli, L., et al. (1996). An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 31, 341–345.

Addolorato, G., Cibin, M., Caputo, F., Caprizzo, E., Gesa, G. L., Stefanini, G. F., et al. (1998). Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in benzodiazepine. Alcohol. Clin. Exp. Res. 23, 1596-1604.

Addolorato, G., Caputo, F., Caprizzo, E., Bernardi, M., Stefanini, G. F., and Gasbarrini, G. (1999b). A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin. Neuropsychopharmacol. 22, 60-62.

Addolorato, G., Castelli, E., Stefanini, G. F., Casella, G., Caputo, F., Marsigli, L., et al. (1996). An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 31, 341–345.

Addolorato, G., Cibin, M., Caputo, F., Caprizzo, E., Gesa, G. L., Stefanini, G. F., et al. (1998). Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in benzodiazepine. Alcohol. Clin. Exp. Res. 23, 1596-1604.
non-responder alcoholic patients. Drug Alcohol Depend. 53, 7–10.
Addolorato, G., Leggio, L., Ferrulli, A., Caputo, F., and Gasbarrini, A. (2009). The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin. Invest. Drugs 18, 675–686.
Agabio, R., Carai, M. A. M., Lobina, C., Pani, M., Reali, R., Vacca, G., et al. (2000). Development of short-lasting alcohol deprivation effect (ADE) in Sardinian alcohol-prefering rats. Alcohol 21, 59–62.
Agabio, R., Colombo, G., Loce, A., Lobina, C., Pani, M., Reali, R., et al. (1998). γ-Hydroxybutyric acid (GHB) reducing effect on ethanol intake: evidence in favour of a substitution mechanism. Alcohol Alcohol. 33, 465–474.
Agabio, R., and Gessa, G. L. (2002). “Therapeutic uses of γ-hydroxybutyrate,” in Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects, eds G. Tunnicliff and C. D. Cash (London: Taylor and Francis), 157–187.
Bell, R. L., Sable, H. J. I., Colombo, G., Hyytia, P., Rodd, Z. A., and Lumeng, L. (2012). Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity. Pharma col. Biochem. Behav. 103, 119–155.
Bernasconi, R., Mathivet, P., Otten, U., Bettler, B., Bishoff, S., and Marescaux, C. (2002). “Part of the pharmacological actions of γ-hydroxybutyrate are mediated by GABAB receptors,” in Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects, eds G. Tunnicliff and C. D. Cash (London: Taylor and Francis), 28–63.
Caputo, E., Addolorato, G., Lorenzini, F., Domenicali, M., Greco, G., del Re, A., et al. (2003). Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 70, 85–91.
Caputo, E., Addolorato, G., Stoppi, M., Arancini, S., Vignoli, T., Lorenzini, E., et al. (2007). Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study. Eur. Neuropsychopharmacol. 17, 781–789.
Caputo, F., Francini, S., Brambilla, R., Vigna-Taglianti, E., Stoppi, M., Del Re, A., et al. (2011). Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur. Neuropsychopharmacol. 21, 450–456.
Caputo, F., Francini, S., Stoppi, M., Lorenzini, E., Vignoli, T., Del Re, A., et al. (2009). Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J. Psychopharmacol. 23, 883–890.
Carai, M. A. M., Agabio, R., Addolorato, G., Gessa, G. L., and Colombo, G. (2005). “Baclofen: preclinical data,” in Drugs for Relapse Prevention of Alcoholism, eds R. Spanghel and K. Mann (Basel: Birkhäuser Verlag), 163–170.
Colombo, G., Lobina, C., Carai, M. A. M., and Gessa, G. L. (2006a). Phe notypic characterization of genetically selected Sardinian alcohol-prefering (sP) and -non preferring (sNP) rats. Addict. Biol. 11, 324–338.
Colombo, G., Serra, S., Vacca, G., Carai, M. A. M., and Gessa, G. L. (2006b). Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-prefering (sP) rats exposed to different alcohol concentrations. Eur. J. Pharmacol. 550, 123–126.
Colombo, G., Serra, S., Brunetti, G., Vacca, G., Carai, M. A. M., and Gessa, G. L. (2003). Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-prefering (sP) rats. Drug Alcohol Depend. 70, 105–108.
Draubel, K. R., Christiansen, J., and Jensen, K. (2006). Gamma-hydroxybutyrate – a drug of abuse. Acta Neur ol. Scand. 114, 145–156.
Eslings, C., Stremmel, W., Grenda, U., and Herrmann, T. (2009). Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-centered randomized study. Am. J. Drug Alcohol Abuse 35, 1899–1902.
Fadda, E., Colombo, G., Mosca, E., and Gessa, G. L. (1989). Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats. Alcohol Alcohol. 24, 447–451.
Gallimberti, L., Canton, G., Gentile, N., Ferri, M., Gabin, M., Fer rara, S. D., et al. (1989). Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 2, 787–789.
Gallimberti, L., Ferri, M., Ferrara, S. D., Fadda, F., and Gessa, G. L. (1992). Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol. Clin. Exp. Res. 16, 673–676.
Gallimberti, L., Spella, M. R., Soncini, C. A., and Gessa, G. L. (2000). Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol and heroin dependence. Alcohol 25, 267–272.
Glisson, J. K., and Norton, J. (2002). Self-medication with gamma-hydroxybutyrate to reduce alcohol intake. South. Med. J. 95, 926–928.
June, H. L., Williams, J. A., Cason, C. R., Devaraju, S., Lin, M., Murphy, J. M., et al. (1995). Low doses of gamma-hydroxybutyric acid (GHB) attenuate ethanol intake in alcohol-preferring (P) rats. Alcohol. Clin. Exp. Res. 19(Suppl. 2), 14A.
Kleber, H. D., Weiss, R. D., Anton, R. F. R., George, T. P., Greenfield, S. F., Kosten, T. R., et al. (2007). Treatment of patients with substance use disorders, second edition. Am. J. Psychiatry 164(Suppl.), 5–123.
Lingenhoehl, K., Brom, R., Heid, J., Beck, P., Froestl, W., Kaumann, K., et al. (1999). γ-Hydroxybutyric acid is a weak agonist at recombinant GABAB receptors. Neuropharmacol ogy 38, 1667–1673.
Maccioni, P., Pes, D., Fantini, N., Carai, M. A. M., Gessa, G. L., and Colombo, G. (2008). γ-Hydroxybutyric acid (GHB) suppresses alcohol’s motivational properties in alcohol-preferring rats. Alcohol 42, 107–113.
Maremmani, I., Lamanna, F., and Tagliamonte, A. (2001). Long-term therapy using GHB (sodium gamma-hydroxybutyrate) for treatment-resistant chronic alcoholics. J. Psy choactive Drugs 33, 135–142.
Martin-Fardon, R., and Weiss, F. (2013). Modeling relapse in animals,” in Drugs for Relapse Prevention of Alcoholism, eds R. Spanghel and K. Mann (Basel: Birkhäuser Verlag), 13–21.
Conflict of Interest Statement: The authors declare that there is no conflict of interest.
Received: 24 August 2012; paper pending published: 25 September 2012; accepted: 17 October 2012; published online: 05 November 2012.
Citation: Colombo G, Carai MAM and Gessa GL (2012) Suppression by γ-hydroxybutyric acid of “alcohol deprivation effect” in rats: preclinical evidence of its anti-relapse properties. Front. Psychi atr. 3:95. doi: 10.3389/fpsyg.2012.00955
This article was submitted to Frontiers in Addictive Disorders & Behavioral Dyscontrol, a specialty of Frontiers in Psychiatry.
Copyright © 2012 Colombo, Carai and Gessa. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original authors and source are credited and sub ject to any copyright notices concerning any third-party graphics etc.